Evidence map›Paper›PMID 42359386›Full record

ReviewNeuro-oncology advances

Genomic drivers of brain metastases in lung cancer.

Ting Wang, Hang Xing, Lei Huang, Hao Zhuang, Jianguo Zhang, Hong Ge, Bo Zhang, Yue Cao, Yining Zhai, Xiaoli Zheng and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ting WangDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Hang XingDivision of Cardiothoracic Surgery, Brown University Health, Alpert Medical School of Brown University, Providence, Rhode Island (H.X.).
Lei HuangDepartment of Pathology, Affiliated Hospital of Nantong University, 20 Xisi Road, Chongchuan District, Nantong, Jiangsu, China.
Hao ZhuangDepartment of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Jianguo ZhangDepartment of Pathology, Affiliated Hospital of Nantong University, 20 Xisi Road, Chongchuan District, Nantong, Jiangsu, China.
Hong GeDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Bo ZhangDepartment of Pathology, Affiliated Hospital of Nantong University, 20 Xisi Road, Chongchuan District, Nantong, Jiangsu, China.
Yue CaoDepartment of Pathology, Affiliated Hospital of Nantong University, 20 Xisi Road, Chongchuan District, Nantong, Jiangsu, China.
Yining ZhaiDepartment of Pathology, Affiliated Hospital of Nantong University, 20 Xisi Road, Chongchuan District, Nantong, Jiangsu, China.
Xiaoli ZhengDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Shanshan BuDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Abbas E AbbasDivision of Hematology/Oncology, Legorreta Cancer Center, Brown University and Brown University Health, Providence, Rhode Island (A.E.A., M.H., B.A.C.).
Matthew HadfieldDivision of Hematology/Oncology, Legorreta Cancer Center, Brown University and Brown University Health, Providence, Rhode Island (A.E.A., M.H., B.A.C.).
Benedito A CarneiroDivision of Hematology/Oncology, Legorreta Cancer Center, Brown University and Brown University Health, Providence, Rhode Island (A.E.A., M.H., B.A.C.).
Liang ChengDepartment of Pathology and Laboratory Medicine, Department of Surgery, Warren Alpert Medical School of Brown University, the Legorreta Cancer Center at Brown University, and Brown University Health, Providence, Rhode Island (L.C.).ORCID https://orcid.org/0009-0004-2260-6254
Yifei LiuDepartment of Pathology, Affiliated Hospital of Nantong University, 20 Xisi Road, Chongchuan District, Nantong, Jiangsu, China.ORCID https://orcid.org/0000-0002-4571-2226

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Brain metastases (BM) significantly affect both prognosis and quality of life in patients with metastatic non-small cell lung cancer (NSCLC), highlighting the need for innovative therapeutic strategies. In this systematic review, we evaluated the prevalence and clinical significance of key genomic alterations in BM from NSCLC. Methods: Comprehensive searches of PubMed, Web of Science, Embase, and the Cochrane Library identified 19 studies encompassing 3028 patients, 930 of whom had BM. Results: Among BM patients, 50% harbored Conclusions: Overall, this study underscores the critical role of genomic profiling in advancing precision medicine approaches and supports the integration of novel targeted and immunotherapeutic strategies to improve outcomes in NSCLC patients with brain metastases. The dynamic evolution of biomarker expression during disease progression and tumor heterogeneity remains major challenges to the development of durable treatment strategies.

Identifiers

PMID42359386
PMCPMC13291917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.